Research Study

 
News Articles for Research Study top ^
Gilead Sciences, Inc. (Nasdaq:GILD) today announced that two Phase 3 clinical trials (Studies 104 and 111) evaluating an investigational once-daily single tablet regimen containing tenofovir alafenamide (TAF) for the treatment of HIV-1 infection in treatment-naïve adults met their primary objectives.
Sign-up for Gilead’s Investigational Tenofovir Alafenamide (TAF)-Based Single Tablet HIV Regimen Meets 48-Week Primary Objective in Two Phase 3 Studies investment picks
http://media.marketwire.com/attachments/201212/109000_36797_HP_Blue_RGB_72_MD.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1151474&ProfileId=051205&sourceType=1 PALO ALTO, CA --
Sign-up for Annual Study Reveals Average Cost of Cyber Crime Escalates 96 Percent to $12.7 Million per Organization investment picks
Landmark Study Reconfirms Oncotype DX® Stratifies DCIS Patient Risk Additional Presentations Include Positive Results from Genomic Health's First Liquid Biopsy Study in Breast Cancer REDWOOD CITY, Calif.
Sign-up for 2014 San Antonio Breast Cancer Symposium to Feature Oncotype DX® DCIS Study in Press Program on Friday, December 12 investment picks
2014 San Antonio Breast Cancer Symposium Presentation Underscores the Value of Oncotype DX® as Chemotherapy Guide SAN ANTONIO , Dec.
Sign-up for Genomic Health Announces Presentation of First Prospective Outcomes Study of Oncotype DX® Breast Cancer Test investment picks
The International Breast Cancer Study Group (IBCSG), Breast International Group (BIG), and Merck, known as MSD outside the United States and Canada, today announced the opening of the PANACEA study, a global collaborative study exploring a new way to treat HER2+ breast cancer that has become resistant to the current standard of care.
Sign-up for International Breast Cancer Study Group, Breast International Group and Merck Announce Opening of International PANACEA Study of Patients with HER2+ Breast Cancer investment picks
Nuvo Research® Completes WF10™ U.S. Market Study for Treatment of Refractory Allergies Canada NewsWire MISSISSAUGA, ON , Oct.
Sign-up for Nuvo Research® Completes WF10™ U.S. Market Study for Treatment of Refractory Allergies investment picks
SANTA ROSA, Calif., Oct.
Sign-up for TriVascular Announces First Patient Enrollment in the LIFE (Least Invasive Fast-Track EVAR) Study investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?docid=0977674001&sourceType=1 http://www.ccnmatthews.com/logos2/Semafo.gif MONTREAL, QUEBEC --
Sign-up for SEMAFO Provides Its Observations to Orbis' Notice of AGM and Updated Scoping Study investment picks
2014/11/6
Horizonte Minerals plc - Infill drilling commenced to support a feasibility study on the Araguaia Nickel Project Canada NewsWire LONDON , Nov.
Sign-up for Horizonte Minerals plc - Infill drilling commenced to support a feasibility study on the Araguaia Nickel Project investment picks
These Studies and Genomic Health's First Liquid Biopsy Study in Bladder Cancer To Be Presented at 2014 Society of Urologic Oncology Annual Meeting, December 3-5 Authors: Isabell Sesterhenn , Timothy Brand , Inger Rosner , Joel Moncur , Amina Ali , Yongmei Chen , Nan Zhang , Athanasios Tsiatis , Dejan Knezevic , Tara Maddala , H.
Sign-up for Results from Second Oncotype DX® Prostate Cancer Test Clinical Validation and First Decision Impact Study To Be Published in European Urology and Urology Practice, Respectively investment picks
PRINCETON, New Jersey and BANGALORE, India , October 27, 2014 /PRNewswire/ -- Infosys and the Institute for Advanced Study (IAS) today announced a new endowment fund that will be used to support visiting scientists and scholars advance their research at the world-renowned institute in Princeton, New Jersey .
Sign-up for Infosys Donates $2 Million to the Institute for Advanced Study to Create a New Fund for Memberships investment picks
Reflecting a proactive stance to ready their firms for the future, independent registered investment advisors (RIAs) are taking steps in the areas of leadership, talent and business legacy planning, according to the results of the latest Independent Advisor Outlook Study (IAOS) released today by Schwab Advisor Services at its annual IMPACT ® 2014 conference.
Sign-up for Schwab Study Finds RIAs Addressing Leadership and Talent to Prepare Firms for the Future investment picks
Clovis Oncology (NASDAQ:CLVS) today announced preliminary Phase 2 results from the ARIEL2 ( A ssessment of R ucaparib I n Ovarian Canc e r Tria l ) study and updated results from the ongoing Phase 1/2 monotherapy study of rucaparib.
Sign-up for Data from Ongoing Phase 2 Studies of Rucaparib in Ovarian Cancer Demonstrate Safety and Clinical Activity, Validate Differentiated Strategy investment picks
Results from First Clinical Study Using NGS-based Proprietary Liquid Biopsy Platform to Detect Presence of Breast Cancer Also Will Be Presented REDWOOD CITY, Calif.
Sign-up for Genomic Health Announces Oral Presentation of Positive Results from Second Large, Independent Clinical Validation Study of Oncotype DX® in DCIS Breast Cancer at 2014 CTRC-AACR San Antonio Breast Cancer Symposium (SABCS) investment picks
2014/9/24
Schwab Advisor Services released the results from a first-of-its kind survey today examining the career paths of independent registered investment advisors (RIAs) and the attributes of the profession that attract talent into its ranks.
Sign-up for Schwab RIA Talent Study Reveals Industry Attributes That Attract Advisors to RIA Profession investment picks
2014/10/2
Three out of four people are not aware that dense breast tissue increases a woman’s risk of developing breast cancer, 1, 2 according to a new global study from GE Healthcare exploring perspectives on breast cancer with an emphasis on understanding awareness around dense breast tissue and the most common symptoms of breast cancer.
Sign-up for GE Healthcare Study: Most People Unaware that Women with High Breast Density are 4 to 5 Times More Likely to Develop Breast Cancer 1 2 investment picks
Across All Subgroups, Patients Treated with Migalastat Compare Favorably to Natural History on Kidney Function (eGFR) CRANBURY, N.J., and SAN DIEGO, Oct.
Sign-up for Amicus Therapeutics Announces Additional Positive Phase 3 Data From Fabry Monotherapy Study 011 investment picks
- Largest Analysis of Data from Patients with Primary Biliary Cirrhosis NEW YORK, Dec.
Sign-up for Intercept Announces Publication of Meta-Analysis From the Global PBC Study Group in Gastroenterology investment picks

Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Research Study
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry |  Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry

Previous: Research Storage  |  Next: Research Subscription